Neumora Therapeutics is trading 5.2% down now at $0.56 on October 1, 2026, with no clearly identified company-specific catalyst. - No new company-specific announcement has surfaced; the latest investor-relations releases are dated August 14 and July 27. - Treasury yields have risen sharply, with the 10-year reaching a 24-year high and pressuring equity sentiment. - Major-index moves are all below 0.5% in the same direction, but available evidence does not establish a market-wide explanation.